全文获取类型
收费全文 | 264630篇 |
免费 | 36654篇 |
国内免费 | 2509篇 |
专业分类
耳鼻咽喉 | 6918篇 |
儿科学 | 10498篇 |
妇产科学 | 6281篇 |
基础医学 | 18906篇 |
口腔科学 | 4285篇 |
临床医学 | 34691篇 |
内科学 | 68572篇 |
皮肤病学 | 10871篇 |
神经病学 | 23471篇 |
特种医学 | 11313篇 |
外国民族医学 | 32篇 |
外科学 | 59551篇 |
综合类 | 1823篇 |
现状与发展 | 72篇 |
一般理论 | 29篇 |
预防医学 | 12703篇 |
眼科学 | 6685篇 |
药学 | 8883篇 |
中国医学 | 329篇 |
肿瘤学 | 17880篇 |
出版年
2023年 | 4882篇 |
2022年 | 1403篇 |
2021年 | 3555篇 |
2020年 | 6383篇 |
2019年 | 2730篇 |
2018年 | 8196篇 |
2017年 | 8032篇 |
2016年 | 9432篇 |
2015年 | 9526篇 |
2014年 | 16934篇 |
2013年 | 17819篇 |
2012年 | 8393篇 |
2011年 | 8446篇 |
2010年 | 12196篇 |
2009年 | 16040篇 |
2008年 | 8874篇 |
2007年 | 7360篇 |
2006年 | 9955篇 |
2005年 | 7368篇 |
2004年 | 6583篇 |
2003年 | 5451篇 |
2002年 | 5488篇 |
2001年 | 10773篇 |
2000年 | 9933篇 |
1999年 | 9038篇 |
1998年 | 5232篇 |
1997年 | 4990篇 |
1996年 | 4665篇 |
1995年 | 4389篇 |
1994年 | 3011篇 |
1993年 | 2660篇 |
1992年 | 5120篇 |
1991年 | 4966篇 |
1990年 | 4604篇 |
1989年 | 4512篇 |
1988年 | 3987篇 |
1987年 | 3732篇 |
1986年 | 3683篇 |
1985年 | 3321篇 |
1984年 | 2481篇 |
1983年 | 2106篇 |
1982年 | 1435篇 |
1981年 | 1311篇 |
1979年 | 2126篇 |
1978年 | 1673篇 |
1977年 | 1504篇 |
1975年 | 1455篇 |
1974年 | 1434篇 |
1973年 | 1426篇 |
1972年 | 1342篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
26.
27.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
28.
Stephan Koter Tina U. Cohnert Korbinian B. Hindermayr Jörg Lindenmann Maximilian Brückner Wolfgang K. Oswald Georg Werkgartner Doris Wagner 《Journal of vascular surgery》2019,69(4):1227-1232
Objective
Low psoas muscle area is shown to be an indicator for worse postoperative outcome in patients undergoing vascular surgical. Additionally, it has been associated with longer durations of hospital stay in patients with cancer who undergo surgery and subsequently greater health care costs in Europe and the United States. We sought to evaluate this effect on hospital expenditure for patients undergoing vascular repair in a health care system with universal access.Methods
Skeletal muscle mass was assessed on preoperative abdominal computed tomography scans of patients undergoing open aortic aneurysm repair in a retrospective fashion. The skeletal muscle index (SMI) was used to define low muscle mass. Health care costs were obtained for all patients and the relationship between a low SMI and higher costs was explored using linear regression and cross-sectional analysis.Results
We included 156 patients (81.5% male) with a median age of 72 years undergoing elective surgery for infrarenal abdominal aortic aneurysm in this analysis. The median SMI for patients with low skeletal muscle mass was 53.21 cm2/kg and for patients without, 70.07 cm2/kg. Hospital duration of stay was 2 days longer in patients with low skeletal muscle mass as compared with patients with normal (14 days vs 11 days; P = .001), as was duration of intensive care stay (3 days vs 1 day; P = .01). The median overall hospital costs were €10,460 higher for patients with a low SMI as compared with patients with a normal physical constitution (€53,739 [interquartile range, €45,007-€62,471] vs €43,279 [interquartile range, €39,509-€47,049]; P = .001). After confounder adjustment, a low SMI was associated with a 14.68% cost increase in overall hospital costs, for a cost increase of €6521.Conclusions
Low skeletal muscle mass is independently associated with higher hospital as well as intensive care costs in patients undergoing elective aortic aneurysm repair. Strategies to reduce this risk factor are warranted for these patients. 相似文献29.
30.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.